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Abstract 8 
The effectivity of different treatment stages at two large wastewater treatment plants (WWTPs) 9 
located in Oslo, Norway, to remove antibiotic resistant Escherichia coli from municipal wastewater 10 
was investigated. The WWTPs were effective in reducing the total cultivable E. coli. The E. coli in WWTP 11 
samples were mainly resistant to ampicillin (6–27%) and trimethoprim-sulfamethoxazole (5–24%), 12 
and, to a lesser extent, tetracycline (3–14%) and ciprofloxacin (0–7%). In the first WWTP, a clear 13 
decrease in the percentage of E. coli resistant to these antibiotics was found, with the main removal 14 
occurring during physical/chemical treatment. In the second WWTP, the percentage of cultivable 15 
resistant E. coli did not display a considerable change. During lab-scale membrane filtration of WWTP 16 
effluents using ultrafiltration (UF) and nanofiltration (NF) membranes, all E. coli, including those 17 
resistant to antibiotics, were removed completely. The results imply that UF and NF processes are 18 
potent measures to remove antibiotic resistant bacteria (ARB) during post-treatment of WWTP 19 
effluents, thus reducing the potential spread of antibiotic resistance in the receiving aquatic 20 
environment.  21 
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Introduction 25 
Antimicrobial resistance (AMR) is a major emerging threat to water quality and human health globally 26 
(WHO 2014). Yet, in Norway it is still regarded as a limited problem with respect to clinically important 27 
microorganisms, and at this point, is considered under control (ECDC 2014; NORM/NORM-VET 2015). 28 
Urban wastewater treatment plants (WWTPs) in which sub-therapeutic concentrations of resistance-29 
driving antibiotics, biocides, and metals continuously co-occur with a high density of diverse 30 
microorganisms, are potential hotspots for antibiotic-resistant bacteria (ARB) as well as for horizontal 31 
gene transfer (Michael et al. 2013; Rizzo et al. 2013). Thus, the ecologically competitive and 32 
challenging environment in biological treatment stages of WWTPs potentially contributes to (i) the 33 
selection of present antibiotic resistance genes (ARGs); (ii) the creation of novel ARGs; (iii) the release 34 
of resistance-driving chemicals; (iv) the dispersal of AMR into the receiving water (Michael et al. 2013; 35 
Berendonk et al. 2015). It is increasingly recognized that WWTP discharges pose a major 36 
anthropogenic source of ARGs being released into the environment. Concurrently, WWTPs are 37 
important nodes where the spread of antibiotic resistance can be controlled/improved before the 38 
effluent is disposed to the water body or reused (Riquelme Breazeal et al. 2013).  39 
Due to the lack of routine monitoring, little is known about the abundance, fate, and removal of both 40 
ARB & ARGs in full scale WWTPs (Rizzo et al. 2013; Colque Navarro et al. 2014; Berendonk et al. 2015). 41 
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In Norway, antibiotic resistance in human health care and veterinary medicine has been stringently 42 
monitored for many years, and is regulated through national strategies and action plans (NIPH 2015; 43 
NMHCS 2015; NORM/NORM-VET 2015). Despite antimicrobial policies in healthcare and food 44 
production seeming to appear successful, this situation is believed to rapidly change if antibiotic 45 
consumption and import of ARB from abroad increases (ECDC 2014; NORM/NORM-VET 2015). In fact, 46 
increase of resistant pathogens in Norway is already registered (ECDC 2014). However, due to focus 47 
on clinical microbes, the role, relevance, and potential risks of antibiotic resistance in environmental 48 
settings, including WWTPs, has received very little attention. This may also explain the lack of research 49 
related to this topic in Norway. While a few pharmaceuticals were quantified in the effluent of two 50 
major Oslo City hospitals, along with influent, sludge, and final effluent at the effluent receiving WWTP 51 
(Thomas et al. 2007b; Langford & Thomas 2009), systematic studies on ARB & ARGs, most of which 52 
are part of international antibiotic resistance screening programs (NORMAN Network1, NEREUS COST 53 
Action2, StARE project3), have only recently been initiated (Tiodolf et al. 2013). 54 
The recent implementation of Europe’s One Health action plan (COM 2017) that recognizes the close 55 
interconnection of human and animal health acknowledges the environment as another important 56 
contributor to the development and spread of AMR in humans and animals. To close knowledge gaps 57 
on the role of AMR in the environment, the action plan calls for an increased effort into monitoring 58 
AMR in environmental settings, and development of risk assessment methodologies that evaluate 59 
risks of AMR to human and animal health. In addition, it requests the development of technologies 60 
that reduce the spread of AMR in wastewater (COM 2017). 61 
Until recently, the research focus of WWTPs has been describing the abundance and relative change 62 
of antibiotic resistance in raw and treated wastewater. Little is known about how the treatment 63 
process and operational conditions in WWTPs influence ARB removal and ARG transfer. Like other 64 
contaminants of emerging concern (CEC), including pharmaceuticals and personal care products, the 65 
fate and spread of ARB & ARGs is expected to be dependent on the type of treatment 66 
process/technology applied at each plant (Rizzo et al. 2013). It will also be influenced by other factors 67 
such as water quality, seasons, climate conditions, and geographical location. Thus, the improvement 68 
or upgrading of WWTPs to minimize AMR contamination of the receiving water calls for an 69 
understanding of what degree the concentration of ARB & ARGs is decreased in WWTPs, or whether 70 
they might even proliferate in such plants. Assuming that 85% of all antibiotics used by humans occurs 71 
at private households (NORM/NORM-VET 2015), of which most end up into the municipal sewage 72 
network, this calls for measures to eliminate antibiotic resistance from wastewater at WWTPs. Such 73 
measures are currently not in place because the actual risk resulting from ARB & ARGs is basically 74 
unknown. Moreover, conventional WWTPs are not designed to completely remove antibiotics and 75 
ARB & ARGs. 76 
Advanced treatment technologies and disinfection downstream of the conventional biological process 77 
could provide further inactivation of ARB and removal of ARGs from WWTP effluents. Those 78 
technologies include the addition of chemical oxidants and disinfectants, UV-C irradiation, ozonation, 79 
advanced oxidation processes (AOP), adsorption, and membrane filtration processes. The latter 80 
include microfiltration (MF), ultrafiltration (UF), nanofiltration (NF), and reverse osmosis (RO), which 81 
may provide a potent alternative for ARB & ARG removal. While only a few studies have investigated 82 
the effect of MF or UF on the removal of ARB & ARGs from real wastewater (Bockelmann et al. 2009; 83 
                                                            
1 Network of reference laboratories, research centers and related organizations for monitoring of emerging     
   environmental substances, http://www.norman-network.net 
2 New and emerging challenges and opportunities in wastewater reuse (ES 1403), http://www.nereus-cost.eu  
3 Water JPI Stopping antibiotic resistance revolution, https://stareeurope.wordpress.com 
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Riquelme Breazeal et al. 2013), the effects of NF and RO membrane filtration, either alone or 84 
combined with other methods, on ARB & ARG removal from WWTP effluent has not been explored. 85 
The first objective of this study was to quantify cultivable Escherichia coli exhibiting resistance to four 86 
selected antibiotics commonly used for medication at Norwegian hospitals; namely ampicillin (Amp), 87 
ciprofloxacin (Cip), tetracycline (Tet), and trimethoprim-sulfamethoxazole (Tmp/Smx), in samples 88 
collected at different treatment stages from two Oslo City WWTPs. This allows to evaluate the 89 
effectivity of the treatment stages to decrease the concentration of ARB, and ultimately on the risk 90 
potential of spread of antibiotic resistance to the Oslofjord. The implementation of tertiary 91 
disinfection technologies to prevent ARB release by conventional WWTPs requires the investigation 92 
of the potential effectiveness, amongst other factors. In the search of feasible methods, membrane 93 
filtration processes pose a potent alternative worthy of further exploration. Hence, the second 94 
objective was to evaluate the efficiency of UF and NF in removal of cultivable E. coli resistant to the 95 
selected antibiotics from WWTP effluents. Based on these results, the feasibility of UF and NF for ARB 96 
& ARG removal during post-treatment at full-scale can be explored. 97 
Methods 98 
Description of WWTPs. Water samples were collected at two full-scale municipal WWTPs in Oslo, 99 
Norway, where wastewater was treated mechanically, chemically, and biologically. As the final 100 
biological treatment step, Vestfjorden Avløpsselskap (VEAS) WWTP applied a biofilm process while 101 
Bekkelaget Vann AS (BEVAS) WWTP used an activated sludge process and dual media filtration (Figure 102 
1). 103 
VEAS WWTP is Norway’s largest WWTP receiving municipal wastewater from a population of 600,000 104 
in both the Oslo and Akershus county areas. The plant receives 100–110 million m3 of urban 105 
wastewater annually, including sewage from five major hospitals in the Oslo area. Coagulant and 106 
polymer are added during the chemical precipitation-sedimentation process. The chemically 107 
enhanced primary treatment is followed by a two-stage biofilm process with post-denitrification 108 
(Figure 1). The biological system consists of nitrification and denitrification fixed-film processes 109 
(BIOFOR®, Degremont), using expanded clay aggregates (Leca, Norway) as medium, with methanol 110 
addition to the denitrification stage. The total hydraulic retention time in the plant is 4 h. The sludge 111 
is treated by anaerobic digestion and drying. The effluent water is discharged into the Oslofjord at a 112 
depth of 30–55 m.  113 
BEVAS WWTP is Norway’s second largest WWTP serving a population of about 290,000 person 114 
equivalents living in the eastern and south eastern parts of Oslo. The plant has an average daily flow 115 
of 100,000 m3/d and a maximum capacity of 260,000 m3/d. The plant annually receives about 116 
40 million m3 of urban (70% of chemical oxygen demand [COD] load) and light industrial wastewater 117 
(30% of COD load; brewery, abattoir, dairy). The raw influent is pre-treated by 3 mm sieving screen, 118 
sand- and fat-trap and pre-sedimentation (Figure 1). The chemically enhanced precipitation-119 
sedimentation process is applied only at higher flow rates, i.e., above the dry weather flow of 2.0 m3/s. 120 
Biological treatment, based on activated sludge process combined with simultaneous precipitation 121 
with iron sulfate, is followed by dual media sand filters. The dual media filters contain Filtralite MC 122 
size 2.5–4 mm (top-layer) and fine-grained sand with particle size of 1.2–2.0 mm (bottom-layer). The 123 
hydraulic retention time in the biological treatment unit is approximately 16 h, with 23 h total 124 
hydraulic retention time. The plants effluent is discharged at a 50 m depth into the Oslofjord.  125 
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a) VEAS WWTP 
 
b) BEVAS WWTP 
Figure 1. Simplified flow sheet of (a) VEAS and (b) BEVAS WWTPs. SP = Sampling point; N = Nitrification; DN = 
Denitrification (Figure b was adapted and modified from Storhaug 2014).  
 126 
Sample collection. Automated 24 h composite samples were collected at the WWTPs from the 127 
influent, after the sedimentation/activated sludge and settling step, and the final effluent (Figure 1). 128 
Influent water at VEAS WWTP contained backwash water from biofilters and from internal return flow 129 
from the sludge treatment. Samples were taken during October 2014 (VEAS) and February 2015 130 
(BEVAS). Samples were transported to the laboratory for immediate experimental analyses. 131 
 132 
Membrane filtration tests. WWTP effluents were subjected to membrane filtration to elucidate the 133 
impact of membrane filtration on ARB removal. A bench scale membrane testing apparatus was used 134 
to evaluate three commercially available membranes in the UF and NF range (Table 1). An effective 135 
membrane area of 99.4 cm2 was used by cutting pieces of different flat sheet and spiral wound 136 
membranes obtained from the manufacturer. Test were done in cross-flow mode at constant pressure 137 
of 1–2 bar (UF) and 6–7 bar (NF) until a volume of 1.4 L of permeate was obtained. Details about the 138 
test system and experimental conditions are described elsewhere (Krzeminski et al. 2017). 139 
 140 
Table 1. Specifications of assessed membranes. UF = Ultrafiltration; NF = Nanofiltration; Da = Dalton. 141 
Membrane 
Filtration 
spectrum 
Molecular weight 
cut off (Da) 
Producer and 
brand name 
Material 
UF UF 10.000 
Alfa Laval,  
UFX-10pHt 
Polysulphone permanently hydrophilic  
NF#1 
NF 
200–400 DOW, NF270 Polyamide thin-film composite 
NF#2 150 Toray, TM600 Piperazine polyamide composite 
 142 
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E. coli quantification and antimicrobial susceptibility assay. E. coli were cultured on Difco MI agar 143 
plates with and without added antibiotics. Difco MI agar was prepared in sterile Milli-Q water 144 
according to the manufacturer’s instruction (Becton Dickinson). The agar was autoclaved (121°C, 15 145 
min) and cooled to 45°C in a water bath. The respective antibiotic compound (all purchased at Sigma-146 
Aldrich) was added to the agar from stock solutions (dissolved in either sterile Milli-Q water, Dimethyl 147 
sulfoxide, or methanol) to the final concentrations stated in Table 2. These antibiotic concentrations 148 
represent the minimal inhibitory concentration (MIC) breakpoint concentrations for testing with E. 149 
coli recommended by the Clinical and Laboratory Standards Institute (CLSI 2003, 2012) and as reported 150 
elsewhere (Watkinson et al. 2007). In addition, Cefsulodin, an inhibitor of gram-positive and some 151 
non-coliform gram-negative organisms, was added (5 µg/mL) to all plates (Brenner et al. 1996). The 152 
medium was mixed well and the agar was instantly dispensed into sterile petri dishes. Control agar 153 
plates contained no antibiotics except for Cefsulodin. 154 
 155 
Table 2. Antibiotics being tested and minimal inhibitory concentration (MIC) breakpoint concentrations used. 156 
ATC = Anatomical Therapeutic Chemical classification 157 
  158 
Antibiotics ATC group  
MIC breakpoint 
(µg/mL) 
Sorption coefficient 
KD (L/kg) 
primary sludge(4) 
Trimethoprim/ 
Sulfamethoxazole  
(CAS 738-70-5/723-46-6) 
J01EE 
 Combinations of sulfonamides and 
trimethoprim 
4/76 (1) 427/3.2 
Ciprofloxacin  
(CAS 85721-33-1) 
J01MA02  
Fluoroquinolones 
4 (2) 2512 
Ampicillin  
(CAS 69-53-4) 
J01CA01  
Penicillins with extended spectrum 
32 (2) -- 
Tetracycline  
(CAS 60-54-8) 
J01AA 
Tetracyclines  
16 (2) 8400 
Cefsulodin  
(CAS 52152-93-9) 
J01DD03 
Third-generation cephalosporin 
antibiotic 
No breakpoint 
concentration. Added 
to 5 µg/mL final 
concentration(3). 
-- 
   1CLSI 2012; 2CSLI 2003; 3Watkinson et al. 2007; 4Eslamian 159 
The antibiotic susceptibility analysis was carried out as reported elsewhere (Watkinson et al. 2007). 160 
For each water sample, two parallel dilution series (in phosphate buffered saline) were filtered 161 
through cellulose nitrate membrane filters (Sartorius, Göttingen, Germany) with 0.22 µm pore size. 162 
Dilutions between 10-1 and 10-4 were filtered together with 10 mL of sterile peptone water (10 g 163 
peptone/L and 5 g NaCl/L). The membrane filters were transferred onto dishes with and without 164 
(control; cefsulodin) antibiotics, followed by incubation for 24 h at 35°C. Blue colonies were then 165 
counted under ambient light, and the results were confirmed at 366 nm UV light. The total 166 
concentration of cultivable E. coli was obtained from control dishes. The percentage of resistance for 167 
each antibiotic was calculated by relating the colony forming unit (CFU) counts on antibiotic-168 
containing plates with the CFU counts on the control plates without antibiotics according to equation 169 
1. The limit of detection was 10 CFU/mL. 170 
 171 
% resistance = 
CFU/mL in medium with antibiotics
CFU/mL in medium without antibiotics
x 100 Eq. 1 
In addition to the plating method, the total concentration of viable E. coli was quantified using the 172 
most probable number (MPN) Colilert Quanti-Tray/2000 method (LOQ: 1 organism/100 mL; IDEXX 173 
Laboratories, Inc.) according to ISO 9308-2:2012. 174 
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Results and Discussion  175 
Abundance of E. coli in WWTPs. The total concentration of viable E. coli decreased considerably (> 176 
2.2 log) across the treatments at both WWTPs (Figure 2). Most E. coli entering VEAS WWTP were 177 
removed by the biofilm process (ca. 2 log), while at BEVAS WWTP, they were gradually removed across 178 
the entire treatment process. However, as expected, no full disinfection was achieved at either plant. 179 
Results obtained by the plating method (LOQ: 10 CFU/mL) were within the 95% confidence interval of 180 
the Colilert MPN method (LOQ: 1 CFU/100mL) (Figure 2).  181 
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a) VEAS WWTP 
 
b) BEVAS WWTP 
Figure 2. Concentration of total viable E. coli in samples collected at (a) VEAS and (b) BEVAS WWTPs. 
Concentrations were measured by the plating method (open symbols) and by Colilert MPN (closed symbols). 
Error bars represent 33% confidence interval, CI, (n=2) for plating method; 95% CI for a single measurement, 
as given by the manufacturer, for the Colilert method. 
 183 
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Decrease in the concentration of antibiotic resistant E. coli in WWTPs. The percentage of cultivable 184 
E. coli resistant to the four investigated antibiotics in the influent was comparable in both WWTPs 185 
(Figure 3).  186 
 
a) VEAS WWTP 
 
b) BEVAS WWTP 
Figure 3. Percentage of antibiotic resistant E. coli in samples collected at (a) VEAS and (b) BEVAS WWTPs. 
Columns represent average measurements with error bars representing 33% confidence interval (n=2). 
 187 
Given that VEAS WWTP receives sewage from several hospitals in the Oslo area (with total capacity of 188 
ca. 2100 beds) and BEVAS WWTP receives no hospital sewage, the comparable percentage of 189 
antibiotic resistant E. coli in the inlet of both facilities implies that the main source of resistance to all 190 
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antibiotics may not be linked to hospital discharges but rather, other sources. In fact, diffuse sources, 191 
and mainly urban household effluent, have been reported to be the major source of ARB in municipal 192 
WWTP influents, while hospital effluents contribute usually less than 1% of the total amount of 193 
municipal sewage (Kümmerer 2004). Hospital inputs of resistance-driving substances to the municipal 194 
sewers system are relatively small (Verlicchi et al. 2012), with the exception of a very limited number 195 
of compounds and sporadic incidences of elevated concentrations in hospital discharged effluents, as 196 
described for VEAS WWTP (Thomas et al. 2007a; Langford & Thomas 2009). Thomas and coauthors 197 
(2007a) showed that two large Oslo City hospitals, Rikshospitalet and Ullevål, only contribute to the 198 
general pharmaceutical load from domestic effluent received at VEAS WWTP. On the other hand, 85% 199 
of the total sales of human antibiotics in Norway are used in primary care, i.e., in the community 200 
outside hospitals (Figure 4); in addition, the contribution of the veterinary sector in total antibiotics 201 
consumption is marginal (ECDC 2014; NORM/NORM-VET 2015). This leads to the assumption that 202 
urban households play a major role in the induction or spread of antibiotic resistance in the municipal 203 
sewage network being detected at the inlet of both WWTPs investigated.  204 
 
Figure 4. Human usage (Defined Daily Doses, DDD, per 1000 inhabitants and per day) of antimicrobial agents 
(ATC group J01) for systemic use in Norway between 2008 and 2012 (source: ECDC 2014). 
 205 
WWTPs display nodes where multiple wastewater streams from different sources with loads of 206 
resistance-driving compounds and ARB & ARGs merge, and where the spread of anthropogenic-207 
derived antibiotic resistance to the environment can be controlled/improved, provided this is 208 
technically feasible.  209 
With caution, our limited set of results suggests that removal of ARB from wastewater could be 210 
performed at the WWTPs rather than at hospitals. We also propose the removal of antibiotics at the 211 
WWTPs as they are not currently removed by the present conventional treatment processes at the 212 
investigated WWTPs (Thomas et al. 2007b). However, this may not necessarily exclude consideration 213 
of implementing effluent point-treatment locally at the hospitals of multi-resistant ARB & ARGs, 214 
specific clinical pathogens, and certain resistant-driving compounds, which are primarily hospital 215 
based and prevail there at elevated concentrations (Kümmerer 2004; Thomas et al. 2007a; Langford 216 
& Thomas 2009). Despite this knowledge, none of the hospitals in Oslo presently treats or separates 217 
its wastewater effluent streams, even though much effort has been made during the past few years 218 
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to implement the ISO-14001 ecological standard that targets to minimize environmental pollution 219 
from hospitals. 220 
For both WWTPs, the percentage of E. coli resistant to Tmp/Smx and Amp in the influent water is 221 
about two-fold higher than for Tet, while the percentage of Cip resistant E. coli is by far the lowest 222 
(Figure 3). Assuming a causal relationship of antibiotic concentration and resistance, this may explain 223 
the difference in the rate of antibiotic resistance observed. Related to antibiotic concentrations, 224 
Thomas and colleagues (2007b) detected lower concentrations of Tet and Cip in the influent of VEAS 225 
WWTP during 5 of 7 measurement incidences, while Tmp and Smx levels were always high. This 226 
behavior was explained by the properties of the antibiotics. Tet and Cip are more hydrophobic and 227 
tend to rapidly sorb to negatively charged particles compared to the more hydrophilic Tmp and Smx, 228 
which are less likely to absorb to particles, and therefore remain in the water phase (Thomas et al. 229 
2007b) (adsorption coefficients are given in Table 2). Tet and Cip will then primarily accumulate in the 230 
sludge, while the other aqueous phase antibiotics are mobile through the downstream WWTP 231 
process, if they are not biodegraded or removed by other physical or chemical means (Thomas et al. 232 
2007b). It is therefore assumed that the lower aqueous phase concentrations of Tet and Cip may pose 233 
a lower selective pressure to develop resistance than the other two antibiotics. Moreover, ARB 234 
resistant to Tet and Cip will mainly be removed by the sludge sedimentation, leading to lower 235 
resistance rates for those agents. Due to sporadic peaks in Tet and Cip concentrations at the influent 236 
of WWTPs (Thomas et al. 2007b), occasionally elevated antibiotic resistance rates for those 237 
compounds could be anticipated. However, to solidify this assumption, more systematic investigations 238 
of the causal relationship of antibiotic concentration and resistance over time are needed.  239 
In VEAS WWTP, the percentage of cultivable antibiotic resistant E. coli decreases in the physical and 240 
chemical treatment, while it does not decrease further by the biofilm process (Figure 3). Hence, it 241 
seems that the fraction of non-resistant E. coli is removed to a somewhat lower extent than the 242 
fraction of antibiotic resistant E. coli. Yet, due to the small number of samples, it remains unclear 243 
whether the decreased percentage of antibiotic resistant E. coli is significant or not. The total 244 
concentration of viable E. coli decreased by 2.4 log during the biofilm process and the percentage of 245 
resistant E. coli mostly remained unchanged. For BEVAS WWTP, the percentage of cultivable antibiotic 246 
resistant E. coli did not change considerably during the treatment processes, and this was independent 247 
of the antibiotic compound (Figure 3).  248 
In spite of WWTPs significantly reducing the total concentration of E. coli, and consequently the 249 
relative fraction of antibiotic resistant organisms, data shows that full disinfection was not achieved. 250 
Therefore, it is assumed that the WWTPs release ARB to the receiving water body, the Oslofjord, to 251 
which WWTPs effluent are discharged at 30 to 55 m depths. The environmental impact on this 252 
ecosystem of ARB & ARGs and periodically high levels of some resistance-driving compounds, such as 253 
Tmp and Cip, being released into the fjord (Thomas et al. 2007b), is currently unknown due to lack of 254 
systematic and long-term studies. While a simple risk assessment has revealed that Cip containing 255 
effluent discharges by VEAS WWTP may at times pose an acute risk to certain aquatic organisms in 256 
the Oslofjord (Thomas et al. 2007a), uncertainty prevails if this is also true for ARB & ARGs, particularly 257 
due to the occurrence of Cip resistance in effluent samples from both WWTPs. Depending on the 258 
quantity and risk of WWTP discharges, they may pose a serious threat to the ecosystem, and may lead 259 
to a rising conflict with various other users potentially affected, such as bathing, fishing, and 260 
recreation. 261 
Membrane filtration removal effectivity. UF and NF membranes were investigated by means of the 262 
membrane filtration test unit for their efficiency to remove antibiotic resistant E. coli from WWTP 263 
effluents. All membranes assessed removed viable E. coli completely below the limit of quantification 264 
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(10 CFU/mL) of the plating method illustrating that the membranes provide a potent hygienic barrier, 265 
as was expected (Figure 5, Table S1). The results from plating were confirmed by the MPN method, 266 
with no E. coli being detected (LOQ: 1 MPN/100 mL) in permeates of the UF (10 kDa) and the NF#2 267 
(150 Da) membranes (Krzeminski et al. 2017). The total removal effectiveness of viable E. coli in the 268 
untreated raw water by WWTP treatment combined with UF was > 4.2 log for both WWTPs. For the 269 
NF#1 membrane (200–400 Da), E. coli was found in the permeate (Krzeminski et al. 2017), but that 270 
was attributed to a sample contamination. The concentrate streams of membrane filtration contained 271 
almost the same concentration of E. coli as the feed, implying that those bacteria were accumulating 272 
in the concentrate streams during operation. Differences are attributed to the method’s precision 273 
(Figure 5).  274 
 275 
While the data suggest that ARB in WWTP effluent can be controlled by UF and NF, no conclusions can 276 
be made with regard to the destruction or removal of ARGs. However, ARGs are the main targets for 277 
disinfection as they display the main risk for spread of antibiotic resistance and are more difficult to 278 
destruct than ARB. For UF and NF membrane processes, ARG removal could be challenging because 279 
DNA is able to penetrate even through UF membranes due to its size, shape, and flexibility 280 
(Arkhangelsky et al. 2008; Arkhangelsky et al. 2011; Riquelme Breazeal et al. 2013). Riquelme and 281 
colleagues (2013) reported significant removal of ARGs spiked to WWTP effluents by means of 282 
membranes of 100 kDa and smaller. Interestingly, the interaction of DNA with wastewater colloidal 283 
particles enhanced the ARG removal by 10 kDa and 1 kDa membranes. The removal of E. coli during 284 
the present study and under the applied operational conditions is assumed to be due to size exclusion 285 
and cell-colloid interactions. However, for the NF experiments, other mechanisms such as electrostatic 286 
interactions with the membrane, may also play a role.  287 
 288 
The results indicate that membrane filtration provides an additional barrier for ARB in wastewater 289 
treatment. Membrane filtration for ARB control may provide several key advantages compared to 290 
other methods as it removes particles and a range of other pollutants, including CECs (Krzeminski et 291 
al. 2017); it provides stable and high quality effluent that can be tailored to the needs enabling fit-for-292 
purpose approach; there is no need for continuous addition of disinfectants; no selection of 293 
resistance; it shows no formation of disinfection by-product; it has a small footprint, plant flexibility, 294 
is field proven, has long-term stability, and robustness. Conversely, based on current research, the 295 
challenges of membrane processes with regard to ARB & ARG removal include (i) possible penetration 296 
of DNA through the UF and NF membranes; (ii) unknown interaction of ARB & ARGs with biofilms 297 
developed on the membrane; (iii) handling of the waste stream containing ARB & ARGs in up-298 
concentrated form; (iv) high energy consumption at large-scale application. Given that the presented 299 
results focused on ARB, future investigations need to clarify if and to what extent membranes provide 300 
a barrier for ARGs. Further research is required to confidently draw conclusions on whether 301 
membrane processes can provide a sufficient barrier for ARB & ARGs, either as stand-alone technology 302 
or as part of a multi-barrier treatment train. 303 
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a) VEAS WWTP 
 
b) BEVAS WWTP 
Figure 5. Concentrations of total viable E. coli (CFU/mL; boxes) and percentage (columns) of antibiotic 
resistant E. coli in the feed (i.e., WWTP effluent), permeate, and concentrate post-treatment with different 
membranes (UF = ultrafiltration; NF = nanofiltration). Feed samples were collected from (a) VEAS and (b) 
BEVAS WWTPs at different dates. Error bars represent 33% confidence interval (n=2).  
 304 
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Conclusions  305 
The results of this study highlight that comparably high concentrations of viable E. coli resistance to 306 
the four antibiotics investigated occur in the effluent of both WWTPs. This suggests that urban 307 
households in the Oslo City area significantly contribute to the spread of antibiotic resistance in the 308 
municipal sewage network, which was detected at the inlet of the WWTPs. The relevance of these 309 
findings will need to be confirmed further by future investigations with more frequent sampling over 310 
longer terms including more statistical analysis. With regard to the relevance of WWTPs in the 311 
spreading of antibiotic resistance, it is important to unravel the causal relationship between antibiotic 312 
consumption, the antibiotics concentration in the wastewater streams of the entire WWTP (water and 313 
sludge), and the rate of antibiotic resistance amongst the prevailing populations. Although this 314 
relationship is described for clinical settings, this is not the case for the environment and requires 315 
further investigation. 316 
  317 
Besides a significant overall reduction of viable E. coli congruent to the reduction in the fraction of 318 
resistant bacteria across the treatment at both WWTPs, full disinfection of the final effluent by 319 
conventional treatment was not achieved and ARB were detected in the WWTP effluents. This may be 320 
critical, considering the release of ARB along with certain antibiotic resistance-driving compounds to 321 
the Oslofjord ecosystem. To ensure effective removal of ARB and ARG destruction in particular, 322 
adequate tertiary treatment methods will need to be assessed and verified for efficient functioning at 323 
full-scale.  324 
 325 
Consideration to the implementation of measures against ARB at WWTPs should include UF and NF, 326 
which may provide effective alternatives for the post-treatment of WWTP effluent to reduce the risk 327 
of ARB release to the receiving aquatic environment. Fortunately, this can be done in parallel with the 328 
removal of other pollutants. Yet, there is still uncertainty if this is also true for the removal of ARGs, 329 
thus further research is required given that ARGs are more difficult to remove and may require 330 
additional treatment of the permeate. 331 
Even though WWTPs are major hotspots for the spread of antibiotic resistance, to date no technical 332 
measures have been introduced at WWTPs to minimize the problem. This may be due to the current 333 
lack of knowledge. In order for decision makers to judge the implementation of measures against the 334 
anthropogenic-induced spread of antibiotic resistance at WWTPs and relevant point-sources, an 335 
improved understanding of (i) the causal relationship of driving factors and organisms responsible for 336 
the spread of antibiotic resistance in full-scale WWTPs, (ii) the effect of the conventional and advanced 337 
treatment on those factors, and (iii) the fate and risk of ARB & ARGs spreading into the downstream 338 
environment, is required. In conclusion, further monitoring data, such as presented in this study and 339 
as outlined in the One Health approach (COM 2017), is required to better assess the risk of ARB & 340 
ARGs in wastewater treatment processes and to develop an action plan to manage the impact on 341 
human and animal health. 342 
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Supplementary Material 350 
Table S1. Concentrations of total viable E. coli from membrane experiments determined by the agar plating 351 
method (LOQ: 10 CFU/mL). Numbers state average values ± 33% confidence interval (n=2). 352 
 353 
WWTP Membrane Sample location cfu/mL 
VEAS 
UF 
(10 kDa) 
Feed 120±18 
Permeate <10 
Concentrate 100 
BEVAS 
UF 
(10 kDa) 
Feed 140±35 
Permeate <10 
Concentrate 75±9 
NF#1 
(200-400 Da) 
Feed 110±53 
Permeate <10 
Concentrate 55±9 
NF#2 
(150 Da) 
Feed 75±44 
Permeate <10 
Concentrate 55±9 
 354 
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